TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Fri Feb 27

NL

Article

TMFBiologyFool published an article 2:55 PM

Whoa, a Profit for Isis Pharmaceuticals Inc.

Don't get too excited just yet.

Thu Feb 26

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Wed Feb 25

NL

Article

TMFBiologyFool published an article 7:42 PM

"Profitability" in Sight for BioMarin Pharmaceutical Inc.

2017 could be the year for the orphan-drug maker.

NL

Article

TMFBiologyFool published an article 1:59 PM

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch

Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.

Tue Feb 24

NL

Article

TMFBiologyFool published an article 10:06 PM

MannKind Corporation in Transition

A drug on the market for two weeks makes for a boring earnings call.

NL

Article

TMFBiologyFool published an article 7:36 PM

Looking Ahead at Exelixis, Inc.

The biotech faces two major value-creating events in 2015.

Fri Feb 20

NL

Article

TMFBiologyFool published an article 4:00 PM

Meet MannKind Corporation's New Boss (No, the Other One)

Sanofi's new CEO Olivier Brandicourt will have an impact on the success of MannKind's Afrezza.

Thu Feb 19

NL

Article

TMFBiologyFool published an article 4:23 PM

5 Things Biogen Idec Inc's Management Wants You to Know

Pipeline data, new drug launches, and sales of established drugs top the list.

Wed Feb 18

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Hidden Gems article.

TMFBiologyFool published an update. 10:00 AM

Tue Feb 17

NL

Article

TMFBiologyFool published an article 3:02 PM

Waiting for the Momenta to Regain

Momenta Pharmaceuticals waits on potential partner(s), the FDA, and the court system.

Thu Feb 12

Rule Breakers article.

TMFBiologyFool published an update. 8:35 PM

NL

Article

TMFBiologyFool published an article 7:25 PM

Loaded-Up Alnylam Pharmaceuticals, Inc. Progresses Its Pipeline

With plenty of cash on hand, Alnylam Pharmaceuticals' fourth-quarter "earnings" call was all about the pipeline.

Wed Feb 11

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

NL

Article

TMFBiologyFool published an article 12:45 AM

Genomic Health, Inc. on the Road to Profitability

A few more quarters of losses to bear first, though.

Tue Feb 10

NL

Article

TMFBiologyFool published an article 7:08 PM

Seattle Genetics, Inc. Exceeds Expecations

You can't ask for more than beating raised guidance, except for profitability, of course.

Mon Feb 9

NL

Article

TMFBiologyFool published an article 3:03 PM

Don't Worry About Orexigen's Obesity Drug EU Approval

Despite what looks initially like bad news for the oral obesity drug, a positive European Commission decision is still likely.

Thu Feb 5

NL

Article

TMFBiologyFool published an article 6:28 PM

What's Bad For Gilead Sciences and Merck Is a Good Sign for Patients

From Breakthrough to me, too.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 96.84
Player Rank 2373 out of 75062
Score 1593.73
Score Change Today +5.20
Accuracy 67.79%
Active Picks 72
Total Picks 213
Best Pick ISIS (+419.62)
Worst Pick INCY (-795.70)
Average Score per Pick 7.48
Charms Earned 11
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts